Gautschi, Oliver, Stadelmann, Carola, Aebersold-Keller, Franziska, Koenig, Katharina, Buettner, Reinhard, Heukamp, Lukas C., Betticher, Daniel, Baumann, Christa, Buser, Katharina, Calderoni, Antonello, Casty, Adrian, D'Addario, Giannicola, Irle, Claudius, Mamot, Christoph, Morant, Rudolf, Trojan, Andreas, Pellicioli, Erica, Jehle-Schwertfeger, Sonja, Aebi, Stefan ORCID: 0000-0002-3383-9449 and Diebold, Joachim (2015). Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. Oncol. Res. Treat., 38 (11). S. 560 - 570. BASEL: KARGER. ISSN 2296-5262

Full text not available from this repository.

Abstract

Background: The role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) and unknown EGFR mutation status has recently been questioned. Patients and Methods: We conducted a retrospective study of patients with unknown EGFR mutation status and long-term response (LTR) to gefitinib in the Swiss lressa expanded access program (EAP). We assessed patient characteristics, and performed Sanger sequencing and next generation sequencing on archived tumor tissue. We hypothesized that EGFR mutations are prevalent in patients with LTR. Results: Of 430 patients in the EAP, 18 (4%) fulfilled our definition of LTR, and 16 of them had archived tumor tissue. Patient characteristics were as expected for age, sex, and smoking history. Median duration of therapy was 38 months (range 24-142 months). Sanger sequencing revealed EGFR exon 18-21 mutations in 6 (38%) of the tumors. Next generation sequencing revealed no further EGFR-mutated cases, but reported in 15 (94%) of the tumors mutations in other genes (ALK, BRAF, DDR2, KEAP1, MET, PTEN, STK11) previously associated with NSCLC. Conclusion: Larger studies are needed to define the prognostic values of different driver mutations in patients with NSCLC. (C) 2015 S. Karger GmbH, Freiburg

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Gautschi, OliverUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stadelmann, CarolaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aebersold-Keller, FranziskaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Koenig, KatharinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buettner, ReinhardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heukamp, Lukas C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Betticher, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baumann, ChristaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buser, KatharinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Calderoni, AntonelloUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Casty, AdrianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
D'Addario, GiannicolaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Irle, ClaudiusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mamot, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Morant, RudolfUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Trojan, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pellicioli, EricaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jehle-Schwertfeger, SonjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aebi, StefanUNSPECIFIEDorcid.org/0000-0002-3383-9449UNSPECIFIED
Diebold, JoachimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-388167
DOI: 10.1159/000441367
Journal or Publication Title: Oncol. Res. Treat.
Volume: 38
Number: 11
Page Range: S. 560 - 570
Date: 2015
Publisher: KARGER
Place of Publication: BASEL
ISSN: 2296-5262
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
PREVIOUSLY TREATED PATIENTS; EXPANDED ACCESS PROGRAM; PHASE-II TRIAL; 1ST-LINE TREATMENT; EGFR MUTATIONS; ERLOTINIB; IRESSA; MULTICENTER; ADENOCARCINOMA; CHEMOTHERAPYMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/38816

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item